EVENTS

2023/11/06
23116-7‘æ9‰ñƒ[ƒuƒ‰ƒtƒBƒbƒVƒ…Eƒƒ_ƒJ‘n–òŒ¤‹†‰ïiZDMM2023j

2023/11/06
V‚µ‚¢ƒnƒCƒXƒ‹[ƒvƒbƒgŒÂ•Ê’`”’”AŽ¡—ÖòƒXƒNƒŠ[ƒjƒ“ƒOƒVƒXƒeƒ€‚̍\’z‚Ɖž—p

2023/04/22
ƒ[ƒuƒ‰ƒtƒBƒbƒVƒ…‘n–ò‚̃Oƒ[ƒoƒ‹“WŠJ

2023/01/01
230101‹Þ‰êV”NŽOd‘åŠwŠCŠÝ‚æ‚è

2022/11/18
“ú–{Š³ŽÒ—R—ˆ‚ª‚ñƒ‚ƒfƒ‹Šw‰ïŠwpW‰ï‚Q‚O‚Q‚Q

tPatient-Derived Cancer Xenograft Zebrafish Model (PDXZ) for Quantitative Drug Discovery Screening

                     
2021/10/13

BioJapan2021: Oct 13-15, 2021
We developed novel zebrafish model for patient-derived xenograft (PDXZ), and demonstrated that PDXZ has high rate and speed of engraftment in normal zebrafish when the immune system is immature, requires less than 100 cancer cells for transplantation, and can be quantitatively analyzed in 2 days. We report on drug efficacy screening system that can be quantitatively analyzed within a week.

ŠÖ˜AƒŠƒ“ƒN

ŽOd‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰ÈƒVƒXƒeƒ€ƒY–ò—Šw

biojapan2021

ŠÖ˜Aƒtƒ@ƒCƒ‹

Patient-Derived Cancer Xenograft Zebrafish Model (PDXZ) for Quantitative Drug Discovery Screening